Verona Pharma plc — Director's Dealing 2023

Oct 24, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2023-10-20

Reporting Person: Rickard Kathleen A. (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-10-20	Ordinary Shares	A	200000	—	Acquired	3072528	Direct

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Represents an award of Restricted Share Units ("RSUs"), each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer. The RSUs vest over four years, with 50,000 RSUs vesting on November 1, 2024 and the balance vesting in 12 equal quarterly installments thereafter.

F3: Consists of (i) 1,751,792 Ordinary Shares underlying RSUs (which are represented by 218,974 ADSs); and (ii) 1,320,736 Ordinary Shares underlying 165,092 ADSs.